DeviceTalks Boston: Here’s what you need to know

Share

Speeding up your medtech innovation

medtech innovation Proto Labs Peter DouglassWe asked Peter Douglass, director of technical operations at Proto Labs (Maple Plain, Minn.) for his thoughts on how medtech can speed up its processes and how those activities tap into innovation. (Douglass will speak about this topic at DeviceTalks Boston on Oct. 2. Check out Proto Labs at Booth 103–104, too.) 

MDO: Research reports have suggested that fast iteration leads to faster product launch, and therefore better market success. But does speed lead to innovation?

Peter Douglass: Absolutely! First, let’s look at it from a time savings perspective. Any reduction in your new product launch timelines is time that can be reallocated to coming up with new ideas. Teams of innovative people aren’t going to sit around twiddling their thumbs if they have extra time. Beyond time savings, speed is something that integrates quick thinking into the everyday culture. If your deadline is reduced from a month to a week you need to become super-efficient at solving problems. This sense of a “crisis” often brings out the best in the shortest amount of time. If you can install that type of thinking into an everyday practice, innovation is one of many things that will benefit.

Read the full story.

And here are more articles with DeviceTalks Boston speakers:

Is there a digital health solution for treating pain? (Frank McGillin, NeuroMetrix’s chief commercial officer)

Want to sell your medtech startup? Be one of these three things (Peter Stebbins, Johnson & Johnson Innovation)

GI Dynamics CEO Scott Schorer is optimistic about Endobarrier’s future: Here’s why

NxStage Medical’s Todd Snell talks FDA, Brexit & regulatory strategy

Did Congress just kill medical device innovation? (Vascular Science’s Mike Drues)

 

Next>>

How do you know your technology is disruptive enough to break conventional wisdom?

textadimage Stan Rowe knows a little something about bringing disruptive technology to market. The current Edwards Lifesciences CSO was in on the ground floor of two of medtech's most disruptive treatments, stents and transcatheter aortic valve replacement.

On December 12th, Rowe will sit down with MassDevice editor Brad Perriello for a long ranging discussion about the inside story on how these technologies came to market and what Rowe learned along the way.


Register now with the code "TAVR" and save 15% today.

Pages: 1 2 3 4 5 6 7 8

Speak Your Mind

*